. 2020 Nov 18;12(11):3426. doi: 10.3390/cancers12113426

Table 5.

Progression-free survival and overall survival according to baseline characteristics.

Variables	Number	Median PFS (Months)	p Value ^a	Median OS (Months)	p Value ^a
Groups
Well differentiated	7	10 (7.434–12.566)	0.013 **	19 (9.224–28.776)	0.154
Moderately differentiated	74	10 (8.057–11.943)		21 (15.527–26.473)
Poorly differentiated	55	6 (3.358–8.642)		11 (6.106–15.894)
Age groups (years)
≤70	87	10 (8.945–11.055)	0.118	21 (15.912–26.088)	0.005 **
>70	49	7 (4.441–9.559)	0.118	11 (6.003–15.997)	0.005 **
Sex
Male	65	8 (5.637–10.363)	0.144	13 (8.755–17.245)	0.716
Female	71	9 (7.731–10.269)	0.144	19 (14.818–23.182)	0.716
BMI group (kg/m²)
≤25	93	9 (7.903–10.097)	0.222	16 (12.009–19.991)	0.003 **
>25	36	10 (7.652–12.348)	0.222	34	0.003 **
Smoking Status
Non-smoker	92	9 (7.958–10.042)	0.384	19 (13.620–24.380)	0.843
Ever-Smoker	44	8 (6.927–9.073)	0.384	17 (12.180–21.820)	0.843
EGFR
Wild-type	58	6 (3.512–8.488)	0.131	13 (8.285–17.715)	0.041 *
Mutation	78	9 (7.848–10.152)	0.131	21 (10.759–31.241)	0.041 *
EGFR-m ^b
Sex
Male	34	9 (6.718–11.282)	0.723	29 (9.052–48.948)	0.696
Female	44	9 (7.701–10.299)	0.723	21 (17.448–24.552)	0.696
EGFR-m & Non-smoker
Sex
Male	20	9 (6.820–11.180)	0.481	14 (9.866–18.134)	0.913
Female	41	10 (8.754–11.246)	0.481	21 (17.429–24.571)	0.913
Treatments
TKI ^c	76	10 (8.938–11.062)	0.140	22 (16.760–27.240)	0.080
Chemotherapy ^d	33	8 (3.981–12.019)	0.140	17 (10.728–23.272)	0.080

^a Log rank test; ^b EGFR-m, EGFR mutation; ^c TKI, gefitinib (Iressa), erlotinib (Tarceva), afatinib (Giotrif), and crizotinib; ^d chemotherapy, pemetrexed (Alimta), gemcitabine (Gemzar), and vinorelbine (Navelbine); PFS, progression-free survival; OS, overall survival. Note: Missing values are excluded. ** p < 0.01, * p < 0.05.